๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
UroGen Pharma Ltd. (URGN)
NASDAQ: URGN ยท Real-Time Price ยท USD
32.33
+2.54 (8.53%)
Nov 19, 2026, 1:44 PM EST - Market open

UroGen Pharma Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
250.25109.7990.482.7164.3648.04
Revenue Growth
159.29%21.45%9.29%28.52%33.96%307.17%
Gross Profit
228.7597.3481.5273.3556.742.89
Operating Income
-30.94-124.86-95.68-65.54-79.04-92.29
Net Income
-65.75-153.49-126.87-102.24-109.78-110.82
Earnings Per Share
-1.31-3.19-2.96-3.55-4.81-4.96
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
90.55120.46241.71141.4799.9689.81
Total Debt
196.28130.09124.92100.21100.061.49
Net Cash (Debt)
-105.73-9.63116.7941.26-0.188.33
Net Cash Growth
--183.09%---12.73%
Net Cash Per Share
-2.11-0.202.721.43-0.003.95

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-131.85-162.44-96.77-76.38-87.56-84.89
Capital Expenditures
-0.2-0.29-0.3-0.19-0.25-0.75
Free Cash Flow
-132.05-162.73-97.06-76.57-87.81-85.64
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
91.41%88.66%90.18%88.68%88.11%89.27%
Operating Margin
-12.36%-113.73%-105.84%-79.23%-122.82%-192.11%
Pretax Margin
-25.64%-139.74%-137.22%-118.87%-167.86%-227.66%
Profit Margin
-26.27%-139.81%-140.35%-123.61%-170.58%-230.67%
FCF Margin
-52.77%-148.22%-107.37%-92.57%-136.45%-178.27%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
5.849.994.975.603.184.44